Connect with us


Prim’s first quarter 2021 revenue down 3.1% to €37.2 million

The Spanish biotech company Prim has recently published its first quarter financial results. The company has reduced its revenues by 3.1%, to $45 million (€37.2 million). The gross operating profit of Prim increased by 7.9%, to $6.4 million (€5.3 million). Prim’s total available liquidity of more than $71.3 million (€58.9 million), showing that the financial strength of the group has increased.



Prim shrinks its sales in the first three months of the year. The Spanish group, which specializes in medical services, closed the first quarter of 2021 with a turnover of $45 million (€37.2 million), 3.1% less compared to the results achieved in the same period of 2020, as reported by the company in a statement sent to the National Securities Market Commission (Cnmv).

The Spanish company justifies these results as a consequence of the “effect of the third wave of the pandemic suffered at the beginning of the year”. The gross operating profit (EBITDA) and operating income reached $6.4 million (€5.3 million) and $4.6 million (€3.8 million), representing an increase of 7.9% and 5.8%, respectively.

On the other hand, the financial strength of the group has increased, with a net financial position of more than $36 million (€29.8 million) and total available liquidity of more than $71.3 million (€58.9 million).

If you want to find more details about Prim’s financial results, download for free our companion app. Born2Invest is a digital media website covering the biotech industry, among others. Our companion app allows you to get your daily dose of financial news from industries like banking, cannabis, innovation in biotechnology.

Prim has a net financial position of more than $36 million (€29.8 million)

During the first quarter, and as a result of the revaluation of the dollar, almost four million euros of losses “on the fair value of derivative instruments recorded in the fourth quarter of 2020” were reversed, the company explains. This variation corresponds to the currency hedging carried out by the company in order to eliminate the risk of foreign currency procurement.

Although the revenue figure for the first quarter of fiscal 2021 was lower than that of the first quarter of the previous year, “the management team is optimistic that, once the situation in the hospitals has been restored and as the population vaccination programs progress, the level of activity can be recovered in the coming quarters, offsetting the drop in activity in the first quarter,” Prim pointed out.

In the chapter on tangible fixed assets, although the investments made since the declaration of the state of alarm have been reduced as much as possible, the investments that were in progress at the beginning of the state of alarm have been completed.

The total amount of investments made was approximately $0.58 million (€0.48 million) for operating investments. In addition, a further $1.16 million (€0.96 million) was invested in long-term leases, which are to be recorded as investments.


(Featured image by mohamed_hassan via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Anthony Donaghue writes about science and technology. Keeping abreast of the latest tech developments in various sectors, he has a keen interest on startups, especially inside and outside of Silicon Valley. From time to time, he also covers agritech and biotech, as well as consumer electronics, IT, AI, and fintech, among others. He has also written about IPOs, cannabis, and investing.